Asprosin‐FABP5 Interaction Modulates Mitochondrial Fatty Acid Oxidation through PPARα Contributing to MASLD Development

Asprosin‐FABP5 Interaction Modulates Mitochondrial Fatty Acid Oxidation through PPARα Contributing to MASLD Development

Abstract Alterations in liver metabolism play a pivotal role in the development and progression of metabolic dysfunction‐associated steatotic liver disease (MASLD). Asprosin is reported to be released from white adipose tissue during fasting and targets the liver. However, the role of asprosin, espe...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yuan‐Yuan Yu, Min Feng, Yi Chen, Hong‐Lin Jia, Qi Zhang, Ming Tong, Yan‐Xi Li, Yu Zhao, Xin‐Xin Liu, Shi‐Feng Cao, Zheng‐kai Wang, Hou‐wei Li, Xue Liu, Yan Zhang
Format:	Article
Language:	English
Published:	Wiley 2025-06-01
Series:	Advanced Science
Subjects:	asprosin FABP5 fenofibrate hepatic steatosis insulin resistance mitochondrial fatty acid β‐oxidation
Online Access:	https://doi.org/10.1002/advs.202415846
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Relationship of asprosin and diabetes: a meta-analysis
by: Xiandong Zeng, et al.
Published: (2025-01-01)

Asprosin is positively associated with metabolic syndrome in hemodialysis patients: a cross-sectional study
by: Jiandong Zhou, et al.
Published: (2023-12-01)

Circulating Asprosin and Neuregulin-4 in metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis
by: Roshan Kumar Mahat, et al.
Published: (2025-05-01)

Asprosin and Neuregulin 4 in Obesity in Children
by: Ramazan Dulkadir, et al.
Published: (2025-04-01)

Association analysis between serum asprosin and metabolic characteristics, Complications in type 2 diabetic patients with different durations
by: Lijing Ma, et al.
Published: (2024-12-01)

Low Serum Asprosin Levels in Fibromyalgia Syndrome: Insights from a Cross-Sectional Study
by: Muhammed Fuad Uslu, et al.
Published: (2025-02-01)

The correlation between serum asprosin and type 2 diabetic patients with obesity in the community
by: Dong Liang, et al.
Published: (2025-05-01)

Relationship between plasma asprosin, dry matter intake, and plasma glucose at different stages of lactation
by: Yinyin Chen, et al.
Published: (2025-05-01)

Concentration of Asprosin Associated with Poor Control of Type 2 Diabetes Mellitus in Diyala Province
by: Alaa Abed Mahmoud, et al.
Published: (2023-06-01)

Systematic review and meta‐analysis of the effect of exercise training on asprosin in randomized controlled trials
by: Mohammad Rahman Rahimi, et al.
Published: (2025-06-01)

Metformin's impact on asprosin and FBN1 expression: Potential mechanisms beyond insulin sensitivity in type 2 diabetes in rats
by: Ali Dashtkar, et al.
Published: (2025-01-01)

Importance of evaluation of heart-type fatty acid binding protein (H-FABP) in COVID-19 Patients
by: Seyhan Ordekci, et al.
Published: (2024-02-01)

Elevated serum asprosin and ANGPTL8 gene expression as novel biomarkers for the diagnosis and prognosis of acute coronary syndrome
by: Zainulabdin Abdulnabi Abdulah Albreej, et al.
Published: (2025-04-01)

Effect of White Tea on Leptin and Asprosin Levels in Rats Feeding a High-Fat Diet
by: Adnan Yilmaz, et al.
Published: (2024-11-01)

FABP4 in Paneth cells regulates antimicrobial protein expression to reprogram gut microbiota
by: Xiaomin Su, et al.
Published: (2022-12-01)

A Cross-Sectional Comparative Study: Could Asprosin and Peptide Tyrosine-Tyrosine Be Used in Schizophrenia to Define the Disease and Determine Its Phases?
by: Elif Özcan Tozoğlu, et al.
Published: (2025-03-01)

MUSTN1 and FABP3 interact to regulate adipogenesis and lipid deposition
by: Yu Fu, et al.
Published: (2025-05-01)

Predictive value of asprosin combined with LAP for metabolic dysfunction associated steatotic liver disease in the physical examination population
by: Dan Lv, et al.
Published: (2025-07-01)

Asprosin Levels in Adults with Type 2 Diabetes Mellitus and Diabetic Kidney Disease: A Systematic Review and Meta-Analysis
by: Ristic J, et al.
Published: (2025-07-01)

PPARα activation attenuated heat-induced myocardial injury in mice
by: Zhoufan Hu, et al.
Published: (2025-09-01)

Is there a relationship between periodontal conditions and asprosin levels in gingival crevicular fluid, saliva and serum?
by: Sedat Tutuş, et al.
Published: (2025-04-01)

Effect of sea buckthorn (Hippophae rhamnoides) on kidney and testicular damage, sperm quality and expression of Irisin and Asprosin in Streptozotocin-Induced diabetic rats
by: Merve Pekince-Özöner, et al.
Published: (2025-06-01)

Metabolic appetite regulation in elderly patients with type 2 diabetes mellitus and the role of asprosin and MIC-1
by: Muharrem Bayrak, et al.
Published: (2025-12-01)

Deficiency of FABP7 Triggers Premature Neural Differentiation in Idiopathic Normocephalic Autism Organoids
by: Xiao Han, et al.
Published: (2025-01-01)

Effect of <i>FABP4</i> Gene Polymorphisms on Fatty Acid Composition, Chemical Composition, and Carcass Traits in Sonid Sheep
by: Jiada Xiang, et al.
Published: (2025-01-01)

FABP4-mediated ERK phosphorylation promotes renal cancer cell migration
by: Evelina La Civita, et al.
Published: (2025-03-01)

Single-cell analysis reveals the loss of FABP4-positive proliferating valvular endothelial cells relates to functional mitral regurgitation
by: Xiaohu Wang, et al.
Published: (2024-12-01)

Single-cell multi-omics reveals that FABP1 + renal cell carcinoma drive tumor angiogenesis through the PLG-PLAT axis under fatty acid reprogramming
by: Yiqiu Wang, et al.
Published: (2025-06-01)

Pleiotropic effects of PPAR-α – from benchside to bedside
by: I. V. Shirinsky, et al.
Published: (2021-06-01)

The role of fatty acid-binding proteins in evaluating kidney involvement in patients with ankylosing spondylitis
by: L. V. Plenkina, et al.
Published: (2020-02-01)

FABP4 as a Mediator of Lipid Metabolism and Pregnant Uterine Dysfunction in Obesity
by: Xuan Li, et al.
Published: (2025-07-01)

Assessment of Serum FABP‐4 Levels in Hypothyroidism Patients: A Comparative Analysis With a Control Group and Their Correlation With Liver Function Tests and Biochemical Factors
by: Mundher Mohammad Hamzeh Aldulaimi, et al.
Published: (2024-11-01)

MicroRNA-668 alleviates renal fibrosis through PPARα/PGC-1α pathway
by: Xinran Wang, et al.
Published: (2024-12-01)

Amelioration of High Fructose Diet-Induced Insulin Resistance, Hyperuricemia, and Liver Oxidative Stress by Combined Use of Selective Agonists of PPAR-α and PPAR-γ in Rats
by: Mahmoud M. Farag, et al.
Published: (2020-04-01)

FABP4 as a therapeutic host target controlling SARS-CoV-2 infection
by: Hatoon Baazim, et al.
Published: (2025-01-01)

RETRACTED ARTICLE: High levels of fatty acid-binding protein 5 excessively enhances fatty acid synthesis and proliferation of granulosa cells in polycystic ovary syndrome
by: Jingyu Liu, et al.
Published: (2024-02-01)

Effects of fenofibrate in patients with type 2 diabetes mellitus complicated by diabetic neuropathy
by: Olga Nikolaevna Tkacheva, et al.
Published: (2010-03-01)

The distinct effects of metformin and imeglimin on high glucose-induced alterations in metabolic function and reactive oxygen species production in mouse Schwann cells are modulated by pemafibrate and/or fatty acid-binding proteins.
by: Hiroshi Ohguro, et al.
Published: (2025-08-01)

<i>FABP4</i> gene expression in subcutaneous and visceral adipose tissue in patients with obesity and type 2 diabetes mellitus
by: K. V. Dracheva, et al.
Published: (2022-07-01)

Ursolic acid suppresses triple-negative breast cancer progression through mediating FABP4/PPARG pathway
by: Ying Deng, et al.
Published: (2025-07-01)